Angle buys 90% stake in cancer diagnostic firm
Angle has increased its stake in its subsidiary, Parsotix, to 90% following the success of the cancer diagnostic firm's cell separation device. The fund the move, Angle raised £1.25m in July, 80% of which has been allocated to Parsortix to fund the definitive validation of its initial findings, wh
Read more